3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide

• ChemBase编号: 72846
• 分子式: C17H14Cl2F2N2O3
• 平均质量: 403.2074664
• 单一同位素质量: 402.03495412
• SMILES: n1cc(c(c(c1)Cl)NC(=O)c1ccc(c(c1)OCC1CC1)OC(F)F)Cl
• Canonical SMILES: FC(Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl)F
• InChI: InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)
• InChIKey: MNDBXUUTURYVHR-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
• IUPAC传统名: 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; roflumilast
• 别名: Daxas; Roflumilast; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; B 9302-107; BY 217; BYK 20869

登记号

• CAS号: 162401-32-3
• PubChem SID: 162037767
• PubChem CID: 449193

理论计算性质

• Acid pKa: 8.182302
• 质子受体: 4
• 质子供体: 1
• LogD (pH = 5.5): 4.4463134
• LogD (pH = 7.4): 4.384677
• Log P: 4.4475408
• 摩尔折射率: 93.9215 cm^3
• 极化性: 35.35955 Å^3
• 极化表面积: 60.45 Å^2
• 可自由旋转的化学键: 7
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: Chlorform; DMSO
• 外观: White to Off-White Solid
• 熔点: 154-158°C

安全信息

• 保存条件: -20°C; -20°C Freezer

产品相关信息

• 成盐信息: Free Base

详细说明

Selleck Chemicals - S2131

Research Area: Metabolic Disease
Biological Activity:
Roflumilast(Daxas) is a selective, long-acting the enzyme PDE-4 inhibitor with an IC50 of 0.8 nM. [1] It has antiinflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such as asthma, and chronic obstructive pulmonary disease. While roflumilast was found to be effective in clinical trials, it produced several dose-limiting side effects including nausea, diarrhoea and headache, and development is continuing in an attempt to minimise the incidence of side effects while retaining clinical efficacy. [2][3]

Toronto Research Chemicals - R639700

Selective phosphodiesterase 4(PDE4) inhibitor. Antiasthmatic; in treatment of chronic obstructive pulmonary disease.

参考文献

• http://en.wikipedia.org/wiki/Roflumilast
• Hatzelmann, A., et al.: J. Pharmacol. Exp. Ther., 297, 267 (2001)
• Schmidt, B.M.W., et al.: J. Allergy Clin. Immunol., 108, 530 (2001)
• Timmer, W., et al.: J. Clin. Pharmacol., 42, 297 (2001)
• Rabe, K.F., et al.: Lancet, 366, 563 (2001)